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Abstract 
Targeting tumors using miniature antibodies is a novel and attractive therapeutic approach, as 
these biomolecules exhibit low immunogenicity, rapid clearance, and high targeting specificity. 
However, most of the small-sized antibodies in existence do not exhibit marked anti-tumor ef-
fects, which limit their use in targeted cancer immunotherapy. To overcome this difficulty in 
targeting multiple biomarkers by combination therapies, we designed a new bifunctional antibody, 
named MaAbNA (multivalent antibody comprised of nanobody and affibody moieties), capable of 
targeting EGFR1 and HER2, which are widely overexpressed in a variety of tumor types. The 
small-sized (29 kDa) MaAbNA, which was expressed in E.coli, consists of one anti-EGFR1 nano-
body and two anti-HER2 affibodies, and possesses high affinity (KD) for EGFR1 (~4.1 nM) and HER2 
(~4.7 nM). In order to enhance its anti-tumor activity, MaAbNA was conjugated with adriamycin 
(ADM) using a PEG2000 linker, forming a new complex anticancer drug, 
MaAbNA-PEG2000-ADM. MaAbNA exhibited high inhibitory effects on tumor cells 
over-expressing both EGFR1 and HER2, but displayed minimal cytotoxicity in cells expressing low 
levels of EGFR1 and HER2. Moreover, MaAbNA-PEG2000-ADM displayed increased tumoricidal 
effects than ADM or MaAbNA alone, as well exhibited greater antitumor efficacy than EGFR1 
(Cetuximab) and HER2 (Herceptin) antibody drugs. The ability of MaAbNA to regulate expression 
of downstream oncogenes c-jun, c-fos, c-myc, as well as AEG-1 for therapeutic potential was 
evaluated by qPCR and western-blot analyses. The antitumor efficacy of MaAbNA and its deriva-
tive MaAbNA-PEG2000-ADM were validated in vivo, highlighting the potential for use of MaAbNA 
as a highly tumor-specific dual molecular imaging probe and targeted cancer therapeutic. 
Key words: EGFR1, HER2 
Introduction 
Epidermal growth factor receptors (EGFRs) are a 
sub-family of four transmembrane receptor tyrosine 
kinases (RTKs), EGFR1-4 (HER1-4). A variety of ex-
tracellular binding ligands, such as EGF, bind and 
activate HER1, HER3 and HER4, whereas HER2 is 
activated via dimerization with other EGFR family 
members [1- 3]. EGFR molecules can mediate cell pro-
liferation as monomers, but their mitogenic effects can 
be exacerbated via inter-receptor interactions. EGFR1 
and HER2 structures (Fig. 1) contain a tyrosine kinase 
domain that is responsible for activation of down-
stream signaling pathways, leading to expression of 
genes related to cell cycle progression, such as c-jun, 
c-fos and c-myc. But this activation (PI3K/Akt and 
Ras/Raf/MEK/ERK) could be inhibited to some ex-








Cetuximab or anti-EGFR1 nanobody) [4, 5] or an-
ti-HER2 antibodies (Herceptin) [6, 7]. Over-expression 
of EGFR1 and/or HER2 has been observed in a vari-
ety of human tumors, and these individual receptors 
are important diagnostic indicators as well as prom-
ising targets for anti-tumor therapy [8- 14]. However, 
accumulating evidence indicates that inhibiting the 
activity of individual EGFRs is insufficient to achieve 
complete clinical response. For example, the thera-
peutic effect of treating tumors with HER2 monoclo-
nal antibody 4D5 can be reversed by EGF-related 
peptides [15]. The complex mechanisms of EGFR 
signaling pathway activation, both autonomous and 
dependent, have necessitated the development of 
combination therapies targeting multiple EGFRs to 
achieve synergetic effects compared to targeting a 
single receptor [16, 17]. Recently, the bifunctional 
small molecule tyrosine kinase inhibitor (TKI) Lapa-
tinib, which targets both EGFR1 and HER2, was 
shown to exhibit enhanced therapeutic efficacy in 
HER2-positive breast cancers [18], although its defi-
ciency in tumor targeting remains a limitation [19]. 
 
 
Figure 1. The mechanism of MaAbNA blocking the EGFR1 and HER2 signaling 
pathways. 
 
In contrast to small molecule TKIs, which lack 
tumor targeting specificity, bivalent and bispecific 
antibodies exhibiting high tumor affinity are being 
widely applied in tumor targeting and therapeutics 
[20]. However, a limitation of targeted antibodies, 
which consist of two monoclonal antibodies (mAbs), 
is their large size, which results in subpar biodistri-
bution profiles and limits their penetration into tumor 
tissue, yielding low tumor-specific accumulation [21]. 
To circumvent this issue, incomplete antibody frag-
ments are being investigated as component forming 
bifunctional proteins which may exhibit enhanced 
tumor penetration. Baeuerle and others reported the 
design and construction of several bispecific antibod-
ies suitable for tumor targeting through the use of 
single chain variable fragment (scFv) or CDR3 regions 
of mAbs [22- 24]. Unfortunately, due to the lack of 
functional units possessed by the complete antibody, 
most of these miniature bivalent antibodies do not 
exhibit appreciable biological activity with respect to 
tumor cell killing [25].  
 Affibody molecules, derived from staphylococ-
cal protein A, are attractive surrogates for full-size 
antibodies in tumor targeting applications due to their 
small size and low immunogenicity [26, 27]. The sin-
gle protein chain of affibodies facilitates direct fusion 
with various proteins. Similarly, nanobodies are small 
biomolecules derived from the heavy-chain of cameli-
dae family [28, 29]. Although these antibodies are de-
void of light chains, their antigen-binding ability is 
retained by integrating the functions of VH and VL 
into a single immunoglobulin (Ig) variable region 
termed VHH, or nanobody. Unlike mAbs, these 
fragments, which are composed of a single Ig fold and 
lacking Fc fragments, expose hydrophobic patches 
that bind to receptors without the need to undergo 
partial unfolding. Additionally, the lack of prote-
ase-sensitive peptide sequences confers higher in vivo 
stability to nanobodies compared to single-chain Fv 
fragments. Until now, in both preclinical and clinical 
settings, the immunogenicity of nanobodies has not 
exceeded predicted levels, presumably due to their 
high degree of homology with human VH domains 
[30]. Genes encoding these nanobodies can be easily 
engineered to obtain multivalent structures, and can 
be fused and recloned into other proteins. He-
negouwen group constructed a biparatopic antibody 
by using two anti-EGFR1 nanobodies, which was ef-
fective at inhibiting tumor cell growth in a xenograft 
model of A431 cells in athymic mice [31]. Addition-
ally, dimeric HER2-specific affibodies and 
EGFR1/HER2 bispecific antibodies, consisting of 
EGFR1 and/or HER2-specific affibodies, were de-
signed by the Lennartsson [32] and Stahl [33] groups, 
respectively, and their in vitro efficacy were evaluated 
using SKOV-3 ovarian cancer cells. To date, all re-
ported bivalent nanobodies and affibodies have ex-
hibited impressive tumor targeting ability, and have 
uses in tumor imaging applications and as tumor 
ligands for drug delivery [34- 37]. However, no study 
was reported to fuse affibody with nanobody to form 
bispecific complex for enhanced targeting and anti-
tumor efficacy, which motivate us to construct an 
affibody-nanobody complex for comprehensive tu-
mor targeting and therapeutic efficacy investigation. 
In this study, we constructed a novel bispecific 




antibody, MaAbNA, by fusing the ZHER2:4 affibody 
[38] to the anti-EGFR1 nanobody 7D12 [39]. Two af-
fibody molecules were used in this construction since 
bivalent affibodies are more effective in tumor imag-
ing and targeting than monovalent affibodies [40, 41]. 
In order to further enhance their tumoricidal activity, 
the widely used anticancer drug adriamycin (ADM) 
was conjugated to MaAbNA using a PEG2000 linker. 
The novel bispecific complex was intensively inves-
tigated both in vitro and in vivo.  
Materials and methods  
Materials 
The pET22b vector and E.coli BL21 were pur-
chased from Novagen and American Type Culture 
Collection (ATCC, USA), respectively. His GraviTrap, 
Sephadex G-15, Sephadex G-75, Sephadex G-100 and 
mono Q anion-exchange columns were obtained from 
GE Healthcare. The hydrophilic near-infrared dye 
ICG-Der-02 (MPA) (EX/EM: 760nm/830nm) was 
prepared in our laboratory [42]. Rhodamine B (MW 
479.01, EX/EM: 540nm/625nm), 1-ethyl-3-(3-dime-
thylamino-propyl) carbodiimide hydrochloride 
(EDCI, MW 191.07), N-hydroxy-succinimide (NHS, 
MW 115.08), N, N-Diisopropylethylamine (DIPEA, 
MW 129.25) and NaBH3CN (MW 62.84) were pur-
chased from Aladdin. RPMI-1640, 3-(4, 
5-dimethylthialzol-a-yl)-2, 5-diphenyltetrazolium 
bromide (MTT), fetal bovine serum (FBS), penicillin, 
streptomycin, and trypsin-EDTA were purchased 
from commercial sources. Adriamycin hydrochloride 
(ADM.HCl, MW 579.99) was purchased from Beijing 
Huafenglianbo Technology Co. Ltd. The EGFR1 an-
tibody (Cetuximab) was purchased from Merck, and 
the HER2 antibody (Herceptin) was from Roche. The 
6×His-tag ELISA kit was from Abcam. 
NHS-PEG2000-ALD was from Xiamen Saigeluobang 
Biological Technology CO. Ltd. Trizol reagent, Re-
verse Transcription kit, and qPCR Master Mix were 
obtained from Promega. Restriction endonucleases 
(NcoI and BamHI) and T4 DNA Ligase were from 
Fermentas. The anti-EGFR1 nanobody 7D12 and 
ZHER2:4 affibody both tagging with 6×His were ex-
pressed and purified by Nanjing Jinsirui Biological 
Technology Co. Ltd. EGF with 6×His-tag was pur-
chased from KeyGEN Biological Technology Co. Ltd. 
ON-TARGET plus siRNA SMART pools against 
EGFR1, HER2, c-myc, AEG-1 and negative control 
were from GE Dharmacon. Primers, BCA kits, all 
primary antibodies used in Western blots, and other 
reagents were from the Shanghai Chemical Reagent 
Company. 
Design and construction of the bispecific 
antibody MaAbNA 
Design and Expression of MaAbNA 
The ZHER2:4 affibody and anti-EGFR1 nano-
body 7D12 were used as the anti-HER2 antibody and 
the anti-EGFR1 antibody, respectively. The recep-
tor-binding domains were linked with G4S (Fig. 2A), 
an established linker with high flexibility and hy-
drophobicity [43]. The gene encoding the sequence of 
NcoI-MaAbNA-BamHI was purchased from Nanjing 
Jinsirui biological technology company. NcoI and 
BamHI sites were designed for insertion into the 
pET22b vector, and the gene sequence of MaAbNA 
was optimized following the codon usage bias of 
E.coli BL21. The amino acid sequence of the MaAbNA 
is show in Fig. 2B. 
After double restriction enzyme digestion, the 
gene encoding the sequence of MaAbNA was inserted 
into the expression plasmid pET22b encoding the 
His6 tag (Fig. 2C). The recombinant plasmid was then 
transformed into E.coli strain BL21, where the 
MaAbNA molecule was expressed as a His6-tagged 
protein. Briefly, a pre-culture of E.coli cells was inoc-
ulated in fresh LB medium containing 100 mg/L am-
picillin and grown in flasks at 37 °C with shaking until 
an attenuance (OD600) of ~0.6 was attained. Protein 
expression was induced by subsequent addition of 
IPTG to a final concentration of 1 mM. After culturing 
for a further 5 h at 37 °C, cells were harvested by cen-
trifugation at 8000 rpm for 10 min at 4 °C. The cell 
pellet was resuspended in Lyse buffer (100 mM 
Tris/HCl, pH 8.0) and disrupted by sonication. After 
centrifugation at 13000 rpm for 30min at 4 °C, the 
pellet was dissolved in binding buffer (8 M urea, 10 
mM Tris/HCl, pH 8.0), and purified on a His Grav-
iTrap column. The Ni-column was washed with a 
concentration gradient of imidazole washing buffers 
(0, 5, 10, 20, 50, 100, 200, 500 mmol/L imidazole, 8 
mol/L urea, Tris/HCl, pH 8.0) to obtain the optimal 
buffer solution. Incorrectly folded protein bounds to 
the column was eluted with imidazole buffer (100 mM 
imidazole, 8 M urea, Tris/HCl, pH 8.0), and refolding 
of the eluted protein was accomplished through dial-
ysis with a concentration gradient of urea buffers (6, 4, 
2, 1, 0.5, 0 mol/L urea, Tris/HCl, pH 8.0). Purification 
of the renatured protein was performed using Se-
phadex G-75 columns and protein was quantified 
using a BCA kit. To confirm the purity and correct 
molecular weight of the protein, the product was an-
alyzed by SDS/PAGE, and the His6-tagged protein 
was identified by Western blot analysis using an An-
ti-His monoclonal antibody. 




Synthesis of MaAbNA-PEG2000-ADM 
MaAbNA-PEG2000-ADM was synthesized in a 
two-step process, as shown in Supplementary Mate-
rial: Fig. S1. NHS-PEG2000-ALD (2 mg), ADM (0.6 
mg) and DIPEA (0.2 mg) were first dissolved in 10 ml 
DMF, and the solution was stirred for 12 hours. After 
purification on a Sephadex G-15 column, the reaction 
product ADM-PEG2000-ALD was obtained. Second, 
ADM-PEG2000-ALD (0.2 mg), MaAbNA (15 mg) and 
NaBH3CN (0.01 mg) were dissolved in 10 ml PBS (pH 
6.5), the solution was stirred at 4 °C for 24 hours, and 
the ALD (propionaldehyde) group was mostly con-
jugated to the N-terminal amino of MaAbNA through 
reductive amination. Using a mono Q anion-exchange 
column, we obtained the purified product 
MaAbNA-PEG2000-ADM, the purification of which 
was determined by HPLC using a Sephadex G100 
column. 
Fluorescence labeling  
The constructed protein MaAbNA along with 
the His6-tagged anti-EGFR1 nanobody 7D12, 
ZHER2:4 affibody and EGF were labeled with the 
visible fluorescence dye RhodamineB for in vitro cell 
study. By controlling the feed ratios and reaction time, 
each antibody or ligand had a similar labeling effi-
ciency with respect to Rhodamine B (molar ratio was 
approximately 1: 2), and at the same molar concentra-
tion, demonstrated equivalent fluorescence efficiency.  
For in vivo study, the home built near infrared 
dye MPA (EX/EM: 760nm/830nm) was used to re-
place RhodamineB for the labeling to all the ligands 
with the similar method.  
In vitro studies 
Cell lines 
Human tumor cell lines (MDA-MB-231, A549 
and MCF-7) and the normal human pulmonary epi-
thelial cell line L2 were all purchased from ATCC and 
used for evaluation of MaAbNA cytotoxicity and cell 
binding affinity. MDA-MB-231 and MCF-7 cells were 
cultured in DMEM medium supplemented with 10% 
FBS, 100 U/ml penicillin and 100 mg/ml streptomy-
cin, while A549 and L2 were cultured in RPMI-1640 
medium supplemented as for MDA-MB-231 and 
MCF-7. Cells were maintained at 37 °C in humidified 
atmosphere containing 5% CO2. 
Primers 
The mRNA sequences of the EGFR1 [GenBank: 
NM_005228.3 (human)], HER2 [GenBank: 
NM_004448.3 (human)], c-jun [GenBank: 
NM_002228.3 (human)], c-fos [GenBank: 
NM_005252.3 (human)], and the housekeeping gene 
GAPDH [GenBank: NM_002046.5 (human)] were ob-
tained from the nucleotide database at the National 
Center for Biotechnology Information (NCBI) website. 
Oligonucleotide primers were designed using Primer 
6 and are listed in Table 1.  
 
Table 1. Oligonucleotides sequence of 5’ and 3’ primers. 
Target gene 5’ primer 3’ primer 
EGFR(Hum) CTGTCCTGTGATGCTGTAA ACTGCCTGGTCTCTGAAT 
HER2(Hum) TCTTGAATGTGGTGGTGTAA TTGCTTGAACTGCTTGAAC 
c-jun(Hum) TGGTAGCAGATAAGTGTTGA CGTGGAGAAGCCTAAGAC 
c-fos(Hum) GCTGACTGATACACTCCAA CTGCTGATGCTCTTGACA 
 
EGFR1 and HER2 expression level analysis in tumor 
cells 
Briefly A549, MDA-MB-231, and MCF-7 cells 
were cultured for 24 hours in 6-well dishes at 37 °C. 
Total RNA was extracted from cells using Trizol rea-
gent, and was dissolved in diethylpyrocarbonate 
(DEPC)-treated water. Total RNA was adjusted to a 
final concentration of 0.1 µg/ml, and reverse tran-
scribed using a Reverse Transcription kit. cDNA 
samples were mixed with primer pairs (EGFR1, HER2 
or GAPDH) and a qPCR Master Mix were prepared 
for subsequent qPCR analyses using the StepOne plus 
Real-Time qPCR system. The results were analyzed 
by using StepOne Software. 
To further investigate the EGFR1 and HER2 ex-
pression level in tumor cells, Western blot analysis 
was performed. After 48 hour incubation, A549, 
MDA-MB-231, and MCF-7 cells were lysed in lysis 
buffer. Proteins were separated on a 12% 
SDS-polyacrylamide gel and transferred onto poly-
vinylidene difluoride membranes (Millipore, USA). 
Membranes were blocked with 10% 
milk/Tris-buffered saline/0.1% Tween 20 for 2 h, in-
cubated with primary antibodies (EGFR1, HER2 and 
β-actin), and incubated with fluorescent secondary 
antibody for 1 h. Fluorescence was visualized with 
enhanced chemiluminescence detection system 
(Amersham, UK), and protein expression was quanti-
fied by densitometry analysis using Quantity One 
software (BioRad). 
In vitro tumor cells targeting 
To assess the in vitro targeting ability, MaAbNA 
was compared to the positive control (anti-EGFR1 
nanobody 7D12, ZHER2:4 affibody) in different tumor 
cell lines using immunofluorescence analysis. Cells 
were seeded in dishes suitable for confocal micros-
copy, incubated for 24 hours, then incubated for 2 
hours in 1 mL of RhodamineB-MaAbNA, Rhoda-
mineB-anti-EGFR1 nanobody 7D12 or Rhoda-
mineB-ZHER2:4 affibody (5 μmol/L). After washing 
with PBS, cells were imaged by a laser confocal mi-




croscope (Olympus FV1100).  
To elucidate the targeting mechanism of 
MaAbNA, blocking experiments with unlabeled (free) 
MaAbNA were conducted on all cell lines cultured at 
37 °C for 24 hours. Free MaAbNA (0.25 mmol/L) was 
added to the cells 30min prior to incubation with 
RhodamineB-MaAbNA, RhodamineB-anti-EGFR1 
nanobody 7D12 or RhodamineB-ZHER2:4 affibody 
for a further 2 hours. After washing with PBS, the cells 
were imaged using laser confocal microscopy. 
Flow cytometric analysis of the FL2 mean fluo-
rescent intensity (MFI) of the cells was used to per-
form a quantitative determination of the tumor tar-
geting ability of MaAbNA. 
Competition ELISA method for antibody affinity de-
termination 
The MaAbNA antibody (approximately 0.5 
nmol/L) was combined with increasing concentra-
tions of EGFR1 or HER2 antigen (0, 500, 1000, 1500 
and 2000 nmol/L), and incubated at room tempera-
ture for 18 h to achieve equilibrium between free 
MaAbNA and MaAbNA-receptor complexes. Subse-
quently, reaction mixtures were added into wells 
precoated with antigen (over-dose), and incubated for 
40 min to ensure that free MaAbNA was completely 
bound to the immobilized antigen. After removing 
the reaction mixture, wells were washed three times, 
and the amount of MaAbNA bound coated antigen 
were quantitated using a Standard ELISA (according 
to the instructions provided by the manufacturer of 
the 6×His-tag ELISA Kit). The affinity of MaAbNA 
binding to EGFR1 or HER2 was calculated using the 
following equation KD= lAilMi/(lM0-lMi) [44], where lAi 
is the molar concentration of antigen combined with 
MaAbNA, lMi is the molar concentration of free 
MaAbNA with a combined antigen concentration of 
lAi, and lM0 is the molar concentration of free MaAbNA 
in the absence of antigen, and (lM0-lMi) represents the 
molar concentration of the MaAbNA-antigen complex 
at equilibrium. Additionally, the affinity of 
MaAbNA-PEG2000-ADM binding to EGFR1 or HER2 
was measured as the same protocol. As a reference, 
the affinity of the anti-EGFR1 nanobody 7D12 for 
EGFR1 and ZHER2:4 affibody binding to HER2 was 
also calculated using this method. 
In vitro competitive inhibition of EGF binding 
As the intrinsic ligand EGF will bind to EGFR1 of 
tumor cells and thus accelerate its proliferation, the 
EGF binding inhibition was carried out. Rhoda-
mineB-EGF (5 μmol/L) was added to tumor cells 
(A549 or MDA-MB-231) growing in confo-
cal-compatible dishes, in the absence or presence of 
free MaAbNA (250 μmol/L). After 2 hour incubation 
at 37 °C, cells were washed with PBS and imaged by 
laser confocal microscopy. 
To further verify the ability of MaAbNA to 
compete with EGF for binding to EGFR1, A549 and 
MDA-MB-231 tumor cells were trypsinized from 
12-well cell culture plates, resuspended in PBS, and 
incubated with RhodamineB-EGF (5 μmol/L). In-
creasing concentrations of free MaAbNA (5, 10, 25, 50, 
250 µmol/L) were added simultaneously to compete 
for EGFR1 binding, and the MFI of the cells was de-
tected by flow cytometry.  
In vitro therapeutic efficacy 
Cell viability assays were carried out to evaluate 
the therapeutic efficacy of MaAbNA and 
MaAbNA-PEG2000-ADM in EGFR1-positive and/or 
HER2-positive cells, A549 and MDA-MB-231, as well 
as their toxicity toward an EGFR1-negative and 
HER2-negative cell line (MCF-7) and a 
non-tumorigenic cell line (L2). The commercial anti-
body drugs (anti-EGFR1 Cetuximab and anti-HER2 
Herceptin) and the widely used anticancer drug 
adriamycin (ADM) were used as positive controls. 
After a 24 hour incubation, MaAbNA, 
MaAbNA-PEG2000-ADM, Cetuximab, Herceptin or 
increasing concentrations of ADM (0.1, 0.2, 0.4, 0.8, 
1.6, and 3.2 μmol/L) were added to the cells growing 
in 96 well plates (n= 6), which were then incubated for 
48 hours. MTT solution (20 mL; 5 mg/mL) was added 
to each well after incubation and the absorbance of the 
solution was measured at 490 nm using a multiwell 
plate reader. 
To further investigate the EGFR1 and HER2 tar-
geted antitumor efficacy of MaAbNA and 
MaAbNA-PEG2000-ADM, EGFR1- or HER2- knock-
down A549 cells were constructed. The RNA inter-
ference assay was done according to the protocols 
provided by the manufacturer of the ON-TARGET 
plus siRNA SMART pools, and the knockdown effects 
were evaluated by western-blot analyses. At 24-hour 
post-transfection of EGFR1 or HER2 siRNA, A549 
cells were seeded into 96-well plates. After 24-hour 
incubation, MaAbNA and MaAbNA-PEG2000-ADM 
(1 or 2 μmol/L) were added to the cells, which were 
then incubated for 48 hours to measure the inhibiting 
rate of cell proliferation. 
Oncogene regulation analysis in tumor cells by 
qPCR 
Briefly A549, MDA-MB-231, and MCF-7 cells 
were cultured for 24 hours in 6-well dishes at 37 °C in 
the presence of either MaAbNA or anti-EGFR1 
nanobody 7D12 (3 μmol/L); non-treated cells were 
included as a negative control. Total RNA was ex-
tracted from cells and tumor tissues using Trizol rea-




gent, and was dissolved in diethylpyrocarbonate 
(DEPC)-treated water. Total RNA was adjusted to a 
final concentration of 0.1 µg/ml, and reverse tran-
scribed using a Reverse Transcription kit. cDNA 
samples were mixed with primer pairs (c-jun, c-fos or 
GAPDH) and a qPCR Master Mix were prepared for 
subsequent qPCR analyses using the StepOne plus 
Real-Time qPCR system. The results were analyzed 
by using StepOne Software. 
Western blot analysis for signaling pathway 
proteins 
A549 cells were seeded in 6-well plates and in-
cubated for 48 hours with MaAbNA (3 μmol/L) or 
anti-EGFR1 nanobody 7D12 (3 μmol/L). Cells were 
divided into three groups respectively for detection of 
Akt S473 phosphorylation (pAkt), c-myc, and AEG-1. 
Cells transfected with c-myc or AEG-1 siRNA were 
used as controls for c-myc or AEG-1 expression; un-
treated cells were included as a control for each 
group. MDA-MB-231 cells treated with MaAbNA (3 
μmol/L) or anti-EGFR1 nanobody 7D12 (3 μmol/L) 
were also used for detection of phosphorylated Akt 
(pAkt). After various treatments for the indicated pe-
riods of time, cells were lysed in lysis buffer; for 
analysis of phospho-protein expression, cells were 
lysed in lysis buffer supplemented with protease in-
hibitor cocktail, 1 mM sodium fluoride, and 1 mM 
sodium orthovanadate. Proteins were separated on a 
12% SDS-polyacrylamide gel and transferred onto 
polyvinylidene difluoride membranes (Millipore, 
USA). Membranes were blocked with 10% 
milk/Tris-buffered saline/0.1% Tween 20 for 2 h, in-
cubated with primary antibodies (pAkt, c-myc, 
AEG-1, Akt, or β-actin), and incubated with fluores-
cent secondary antibody for 1 h. Fluorescence was 
visualized with enhanced chemiluminescence detec-
tion system (Amersham, UK), and protein expression 
was quantified by densitometry analysis using Quan-
tity One software (BioRad). 
Animal experiments 
Animal models 
All animal experiments were carried out in 
compliance with the Animal Management Rules of 
the Ministry of Health of the People's Republic of 
China. A549, MDA-MB-231 and MCF-7 cells (5×106) 
were injected subcutaneously into the upper axillary 
fossa of nude mice (Charles River Laboratories, n = 10 
per group). When tumor size reached 0.3- 0.4 cm in 
diameter, mice were used for NIR imaging and 
treatment. For pharmacokinetic studies, Lewis rats 
were used (Charles River Laboratories, n= 10 per 
group). 
Tumor targeting in tumor bearing mice  
To investigate the dynamic distribution and tu-
mor targeting ability of MaAbNA in nude mice, 
MPA-MaAbNA (50 nmol/kg) and the positive control 
(MPA-anti-EGFR1 nanobody 7D12, MPA-ZHER2:4 
affibody) were injected intravenously and the fluo-
rescence imaging was performed at various time 
points post-injection using an NIR imaging system. 
Free MaAbNA (2.5 μmol/kg) was used in blocking 
experiments. The tumor/normal tissue ratios (T/N 
ratio) were analyzed and compared using the analysis 
region of interests (ROI) function.  
In vivo competitive inhibition of EGF 
tumor-binding 
To investigate the ability of MaAbNA to com-
pete with intrinsic EGF for binding to EGFR1 in vivo, 
A549 and MDA-MB-231 tumor-bearing mice were 
divided into 2 groups, one of which received 
MPA-EGF (50 nmol/kg) via intravenous injection 
while the other received MPA-EGF (50 nmol/kg) to-
gether with free MaAbNA (2.5 μmol/kg) in order to 
evaluate competitive blocking. Fluorescence imaging 
of the mice was performed using an NIR imaging 
system at various time points post-injection, and the 
tumor/normal tissue ratios (T/N ratio) were ana-
lyzed and compared using the analysis region of in-
terests (ROI) function. 
Pharmacokinetics of MaAbNA and 
MaAbNA-PEG2000-ADM 
Lewis rats were divided into 2 groups (n= 6) for 
intravenous administration of MaAbNA and 
MaAbNA-PEG2000-ADM (300 nmol/kg). At 0.5, 2, 4, 
6, 8, 12, 24, 48 and 72 hours post injection, blood sam-
ples were obtained from the fossa orbitalis, and se-
rum concentrations of MaAbNA and 
MaAbNA-PEG2000-ADM were quantified using a 6×
His-tag ELISA Kit. Serum drug levels were analyzed 
using WinNonlin pharmacokinetic software. 
In vivo antitumor efficacy 
A549 tumor-bearing mice were randomly di-
vided into 6 groups (n= 6 per group), and treated 
every other day for 15 days via tail vein injection with 
0.2mL of the following: (A) Saline (control group); (B) 
ADM (400 nmol/kg); (C) Cetuximab (400 nmol/kg); 
(D) Herceptin (400 nmol/kg) (E) MaAbNA (400 
nmol/kg); and (F) MaAbNA-PEG2000-ADM (400 
nmol/kg). The therapeutic efficacies and systematic 
toxicities of MaAbNA and MaAbNA-PEG2000-ADM 
were evaluated based on daily measurements of tu-
mor volume and body weight. Upon completion of 
treatment (15 days), mice were sacrificed and the re-
sected tumors were photographed, and along with 




hearts and kidneys to be processed from histologic 
examination. 
Statistical analysis 
Data were expressed as mean ± SD. Statistical 
analysis was conducted using a Students t-test, with 
statistical significance assigned to a P value lower 
than 0.05. 
Results 
Identification and characterization of 
MaAbNA 
The experimental design and method of 
MaAbNA expression are shown in Figures 2A and 2C. 
MaAbNA was initially purified by His GraviTrap 
column, with lanes 1- 8 representing the proteins 
eluted from His GraviTrap column with wash buffer 
containing increasing concentrations of imidazole (0, 
5, 10, 20, 50, 100, 200 and 500 mmol/L imidazole, re-
spectively) (Fig. 2D). The intense signal in lane 6 with 
an approximate molecular weight of 29 kDa indicates 
that the target protein constitutes a large portion of 
the crude products. The crude product was further 
purified using a Sephadex G-75 column and subse-
quently analyzed by SDS-PAGE (Fig. 2E). Gray level 
difference analysis indicated purity of up to 90%. To 
further confirm the identification of the target protein, 
Western blot analysis using an anti-His antibody de-
tected a protein with molecular weight of 29 kDa as 
our targeted protein (Fig. 2F). MaAbNA exhibited a 
single absorption peak at 280 nm (Fig. 2G). Using the 
BCA kit, we determined the protein concentration of 
the fermentation liquid to be 1.7 mg/L. 
 
Figure 2. Design (A) and amino sequence (B) of MaAbNA. C, construction and expression of MaAbNA. SDS-PAGE analysis of MaAbNA purified by His GraviTrap 
column (D), then by Sephadex G-75 (E). F, Western Blot analysis of MaAbNA using anti-His6 antibody. G, the absorption spectra of MaAbNA and 
MaAbNA-PEG2000-ADM. H, HPLC map of MaAbNA-PEG2000-ADM. 





Figure 3. A, qPCR analysis of EGFR1/GAPDH and HER2/GAPDH in A549, MDA-MB-231 and MCF-7 cancer cells. B, Western Blot analysis of EGFR1 and HER2 
expressing in A549, MDA-MB-231 and MCF-7 cells. Data are given as mean±SD (n=5). 
 
Identification and characterization of 
MaAbNA-PEG2000-ADM 
Due to the presence of NaBH3CN, the ALD 
(propionaldehyde) group can be conjugated to the 
only primary amine groups in MaAbNA through re-
ductive amination [45, 46]. In the peptide chain of 
MaAbNA, the only primary amines are the ε-amino 
groups in the side chain of lysine and N terminal 
α-amino groups. Additionally, the N terminal 
α-amino is more nucleophilic than the ε-amino at pH 
6.5 [47], providing higher selectivity for the N termi-
nal α-amino to be conjugated to ALD group through 
reductive amination. All of these had provided a fea-
sible scheme to make an N terminal site-directed 
PEGylation of MaAbNA, with a final product of 
MaAbNA-PEG2000-ADM (Supplementary Material: 
Fig. S1). 
As shown in Fig. 2G, MaAbNA-PEG2000-ADM 
exhibits three absorption peaks at 243 nm (PEG2000), 
280 nm (MaAbNA), and 479 nm (ADM), confirming 
successful synthesis. In addition, a single peak of 
MaAbNA-PEG2000-ADM with a retention time of 
13.1 min is observed by HPLC (Fig. 2H), reflecting a 
purity of greater than 90%. Moreover, 
MaAbNA-PEG2000-ADM was quantified using a 6×
His-tag ELISA Kit, while the ADM component was 
quantitated based on an ADM (OD 479) standard 
curve, which together indicated a modified 
ADM/MaAbNA ratio of 1: 1. 
Expression level of EGFR1 and HER2 in tumor 
cells 
To assess the correlation between the combined 
EGFR1/HER2 expression and the targeting and 
therapeutic abilities of MaAbNA, mRNA transcrip-
tion levels of EGFR1 and HER2 were investigated in 
tumor cell lines (A549, MDA-MB-231, MCF-7) (Fig. 
3A). The expression of EGFR1 and HER2 in the dif-
ferent cancer cells decreased in the following order: 
A549 > MDA-MB-231> MCF-7; MDA-MB-231 and 
MCF-7 cells did not exhibit significant expression of 
HER2. Gene expression results were confirmed by 
Western blot analysis as shown in Fig. 3B.  
In vitro tumor-targeting ability 
 To investigate the specificity of the small-sized 
MaAbNA antibody for tumor cells over-expressing 
EGFR1 and/or HER2, we evaluated the binding of 
RhodamineB-MaAbNA to A549 cells (EGFR1 and 
HER2 positive), MDA-MB-231 cells (EGFR1 positive), 
and MCF-7 cells (EGFR1 and HER2 negative). Rho-
damineB-anti-EGFR1 nanobody 7D12 and Rhoda-
mineB-ZHER2:4 affibody were included as positive 
controls. The fluorescence intensity of A549 cells in-
cubated with RhodamineB-MaAbNA was higher than 
that incubated with RhodamineB-anti-EGFR1 nano-
body 7D12 or RhodamineB-ZHER2:4 affibody, but the 
fluorescence intensity of MDA-MB-231 cells incubat-
ed with RhodamineB-MaAbNA was similar to that 
incubated with RhodamineB-anti-EGFR1 nanobody 
7D12 (Fig. 4A). The mean fluorescence was illustrated 
in Fig. 4B. Moreover, tumor cell lines overexpressing 
EGFR1 (A549 and MDA-MB-231) exhibited higher 
fluorescence intensity than MCF-7 cells (Figs. 4A, B). 
Pre-treatment with free MaAbNA inhibited the bind-
ing of RhodamineB-MaAbNA, Rhoda-
mineB-anti-EGFR1 nanobody 7D12 and Rhoda-
mineB-ZHER2:4 affibody (Fig. 4), confirming the 
binding of MaAbNA and its ability to selectively tar-
get cell membrane receptors (EGFR1 and HER2) on 
A549 and MDA-MB-231 cells.. 
To quantitatively assess cellular binding of 
RhodamineB-MaAbNA to A549, MDA-MB-231, and 
MCF-7 cells, we performed flow cytometric analysis 
under blocking and non-blocking conditions (Fig. 5). 
The mean fluorescence intensity (MFI) in the tumor 
cells decreased in the following order: A549 (MFI: 
446)> MDA-MB-231 (MFI: 170)> MCF-7 (MFI: 58), 
consistent with the receptor expression levels. In ad-
dition, A549 and MDA-MB-231 exhibited a much 
higher MFI than their blocked counterparts, indicat-
ing the specificity of MaAbNA to EGFR1 and HER2 
receptors. 




Quantitative affinity determination by 
competitive ELISA assay 
To further confirm the specificity of MaAbNA to 
EGFR1 and HER2, the competitive ELISA was per-
formed. As shown in Supplementary Material: Fig. 
S2A, increasing concentration of antigen (lAi) EGFR1 
induced a linear increase in combined/free ratio of 
MaAbNA [(lM0- lMi)/lMi] (with R2 > 0.998), 
which ensured the accuracy of the affinity coefficient 
KD calculated as KD= lAilMi/(lM0-lMi). The affinity val-
ues of MaAbNA, MaAbNA-PEG2000-ADM and an-
ti-EGFR1 nanobody 7D12 binding to EGFR1 are ~4.1, 
~6.9 and ~3.5 nM, respectively. From Supplementary 
Material: Figure S2B, the affinity value of MaAbNA, 
MaAbNA-PEG2000-ADM and ZHER2:4 affibody 
binding to HER2 were calculated as ~4.7, ~7.2 and 
~47.9 nM, respectively. 
Each MaAbNA molecule is comprised of one 
anti-EGFR1 nanobody and two ZHER2:4 affibodies, 
and exhibits an EGFR1 binding affinity similar to an-
ti-EGFR1 nanobody, indicating that the activity of the 
EGFR1 binding site was not significantly impaired by 
fusion of the proteins. In addition, the HER2 affinity 
of the bivalent ZHER2 domains of MaAbNA (~4.70 
nM) showed a significant improvement compared to 
the monovalent affibody (~47.9 nM), which confirmed 
the correct design of double HER2 targeting domains. 
Furthermore, compared with free MaAbNA (~4.1 nM 
for EGFR1 and ~4.7 nM for HER2), 
MaAbNA-PEG2000-ADM exhibited similar affinity to 
EGFR1 (~6.9 nM) and HER2 (~7.2 nM), demonstrating 
that the activities of the EGFR1 and HER2 binding 
sites were not significantly impaired by the 
PEG2000-ADM conjugation. 
It was noticed that the KDs of the anti-EGFR1 
nanobody 7D12 and ZHER2:4 affibody (~3.5 and 
~47.9 nM) were similar to that measured by Biacore 
(~2.3 and ~50 nM) [38, 48], confirming that competi-
tion ELISA is an effective method for evaluating an-
tibody affinity [49, 50]. 
 
Figure 4. A, laser confocal fluorescence microscopy images of cells (A549, MDA-MB-231 and MCF-7) incubated with different fluorescent probes (MaAbNA, 
anti-EGFR1 nanobody 7D12 and ZHER2:4 affibody), with or without blocking dose of free MaAbNA. B, mean fluorescence intensity of cells treated with the three 
fluorescent probes, while MaAbNA-treated cells were compared to the block. C, mean fluorescence intensity of cells treated with anti-EGFR1 nanobody 7D12 and 
ZHER2:4 affibody probes, compared to the blocking by free MaAbNA. Data are given as mean±SD (n=5). *P <0.05. 





Figure 5. A, quantitative cellular binding (A549, MDA-MB-231 and MCF-7) of MaAbNA probe, additionally compared with the block. B, mean fluorescence intensity 
of MaAbNA-treated cells with different EGFR1+HER2 expression level. Data are given as mean±SD (n=5). 
 
In vitro competitive inhibition of EGF binding 
As the intrinsic EGF will bind to EGFR1 of tumor 
cells and thus accelerate its proliferation, the EGF 
binding inhibited by MaAbNA was performed here. 
As shown in Figures 6A and 6B, free MaAbNA effec-
tively inhibited the cellular binding of Rhoda-
mineB-EGF. Furthermore, as the concentration of 
MaAbNA increased, the MFI of A549 and 
MDA-MB-231 treated simultaneously with Rhoda-
mineB-EGF gradually decreased (Figs. 6C, D), 
demonstrating a dose-dependent effect of MaAbNA 
on the competitive inhibition of standard ligand EGF 
binding to EGFR1, thus indicating the potential of 
MaAbNA to inhibit EGF-driven tumor cell prolifera-
tion.  
In vitro therapeutic efficacy  
 In order to evaluate the therapeutic efficacy of 
MaAbNA and MaAbNA-PEG2000-ADM as well as 
their potential cytotoxicity, cell viability assays were 
performed using tumor cell lines A549, MDA-MB-231, 
MCF-7, and normal cell line L2. As shown in Figs. 7A 
and B, MaAbNA and MaAbNA-PEG2000-ADM ef-
fectively reduced the viability of A549 (EGFR1- and 
HER2- positive) and MDA-MB-231 (EGFR1-positive, 
HER2-negative) cells. MaAbNA displayed a higher 
therapeutic efficacy in A549 cells than either the 
commercial antibody drugs (anti-EGFR1 Cetuximab 
and anti-HER2 Herceptin) or the commonly used an-
ticancer drug ADM (Fig. 7A). Moreover, in 
MDA-MB-231 cells over-expressing only EGFR1, 
MaAbNA displayed a higher therapeutic efficacy than 
anti-HER2 Herceptin, but exhibited a similar efficacy 
to anti-EGFR1 Cetuximab (Fig. 7B). Importantly, 
MaAbNA-PEG2000-ADM exhibited higher therapeu-
tic efficacy than ADM, MaAbNA and control anti-
bodies in both A549 and MDA-MB-231 cells with high 
receptor expression (Figs. 7A, B), highlighting its im-
proved antitumor activity versus MaAbNA alone, 
and further confirming a role for MaAbNA in deliv-
ering anti-tumor drugs to EGFR1 and/or HER2 posi-
tive tumor cells. MaAbNA and 
MaAbNA-PEG2000-ADM were minimally cytotoxic 
toward low receptor expression cells MCF-7 and L2 
(Figs. 7C, D), so were Cetuximab and Herceptin, 
whereas ADM was highly cytotoxic to all cell lines 
(Fig. 7). 
To further investigate the EGFR1 and HER2 tar-
geted antitumor efficacy of MaAbNA and 
MaAbNA-PEG2000-ADM, EGFR1- or HER2- knock-
down A549 cells were constructed. At 48-hour 
post-transfection of EGFR1- and HER2- siRNA, 
EGFR1 and HER2 expressions in A549 cells were ef-
fectively knocked down, and the knockdown effects 
were kept until 96-hour post-transfection, indicating 
that the gene knockdown cells were suitable to be 
applied in MTT assay (Fig. 8A). As shown in Figures 
8C and 8D, MaAbNA and MaAbNA-PEG2000-ADM 
displayed significant higher inhibitory effects on 
non-transferred A549 than either EGFR1- or HER2- 
knockdown cells. The therapeutic efficacies of 
MaAbNA and its drug conjugated were consistent 
with the expression level of EGFR1 and HER2, 
demonstrating their specificities to both of the recep-
tors. 




Taken together, these results suggest that 
MaAbNA antibody and MaAbNA-PEG2000-ADM are 
promising anticancer drugs for EGFR1- and/or 
HER2- overexpressing tumors. 
 
Figure 6. A, the competitive inhibition of EGF cell-binding conducted by free MaAbNA, which was imaged by a laser confocal microscope. B, mean fluorescence 
intensity of cells, which was detected by a laser confocal microscope. The competitive inhibition of EGF-binding to A549 (C) and MDA-MB-231 (D) cells by increasing 
concentrations of free MaAbNA, which was detected by flow cytometer. Data are given as mean±SD (n=5). *P <0.05. 
 
Figure 7. In vitro antitumor efficacy and cytotoxicity. Cell viability of A549 (A), MDA-MB-231 (B), MCF-7 (C), and L2 cells (D), incubated with MaAbNA, Cetuximab, 
Herceptin, ADM or MaAbNA-PEG2000-ADM. Data are given as mean±SD (n=5). 





Figure 8. A, EGFR1 and HER2 expression in A549 cells at 48 and 96-hour post-transfection of EGFR1 or HER2 siRNA. In vitro inhibiting ability of MaAbNA and 
MaAbNA-PEG2000-ADM on EGFR1 (B) and HER2 (C) knockdown A549 cells. Data are given as mean±SD (n=5). *P <0.05. 
 
Down-regulation of oncogenes in cells 
conducted by MaAbNA 
C-jun and c-fos genes are regulated downstream 
of EGFR1 and HER2 [51, 52]. The dimer of c-fos and 
c-jun comprises the AP-1 early response transcription 
factor, which is closely related to the invasive capa-
bility of tumor cells. Down-regulation of c-jun and 
c-fos are important indexes of tumor therapy, there-
fore alterations in c-jun and c-fos transcription pro-
vides evidence for the binding function of MaAbNA 
to EGFR1 and HER2, and reduced expression of these 
genes will result in inhibition of downstream signal-
ing, ultimately arresting tumor cell growth. To inves-
tigate the regulatory role of MaAbNA on tumor cell 
progression, c-jun, and c-fos mRNA transcription 
levels were assessed before and after MaAbNA 
treatment, or after treatment with anti-EGFR1 nano-
body 7D12 as a positive control (Fig. 9). Transcription 
of c-jun and c-fos were significantly down-regulated 
after incubation of A549 cells with MaAbNA (P< 
0.05). Changes in gene expression were also observed 
in A549 cells treated with the anti-EGFR1 nanobody 
7D12, but to a much lesser extent than in 
MaAbNA-treated cells. This is presumably due to 
activation of downstream signal transduction path-
ways not only by binding of EGF to EGFR1 but also 
by autophosphorylation of heterodimeric 
EGFR1/HER2 receptors in HER2-overexpressing tu-
mors [53]. For A549 cells, which overexpress both 
EGFR1 and HER2, MaAbNA is predicted to have du-
al-receptor targeting ability and thus exhibit a 
stronger inhibitory effect on oncogenic signaling than 
the monovalent anti-EGFR1 nanobody 7D12. As ex-
pected, expression of both c-fos and c-jun were simi-
larly down-regulated in MDA-MB-231 cells treated 
with MaAbNA compared to anti-EGFR1 nanobody 
7D12 treatment; however, the degree of 
down-regulation was lower than that observed in 
A549. In A549 cells treated with MaAbNA, c-fos and 
c-jun expression decreased by 73% and 72%, respec-
tively, while in MDA-MB-231 c-fos and c-jun expres-
sion decreased by only 50% and 55%, respectively. In 
comparison, gene expression decreases were 32% and 
29% (A549 cells) and 53% and 62% (MDA-MB-231 
cells) following nanobody treatment, and no obvious 
down-regulation of c-fos or c-jun was observed in 
MCF-7 cells.  
Regulation of signal transduction pathways by 
MaAbNA in A549 cells  
Expression of the AEG-1 oncogene is closely re-
lated to tumor migration and invasion [54, 55], and is 
mediated by Ha-ras and the associated signaling 
pathway shown in Fig. 10A. Ha-ras activates the PI3K 
signaling cascade, resulting in increased c-myc ex-
pression and binding of Myc-Max to the AEG-1 pro-
moter, augmenting AEG-1 expression. AEG-1 acti-
vates the NF-κB pathway, which regulates expression 
of genes involved in migration and invasion and thus 




plays a crucial role in Ha-ras-mediated tumor pro-
gression [56]. C-myc is a proto-oncogene which is 
frequently found to be up-regulated in many types of 
cancers. Myc overexpression stimulates gene ampli-
fication, presumably through DNA over-replication 
[57]. 
Introduction of either c-myc or AEG-1 siRNA 
similarly and effectively down-regulated AEG-1 ex-
pression, suggesting interplay between c-myc and 
AEG-1 (Fig. 10B). Comparing with the non-treated 
control, treatment of A549 cells (EGFR1- and HER2- 
overexpressing) with MaAbNA effectively inhibited 
c-myc and AEG-1 expression by decreasing Akt (S473) 
phosphorylation, while the anti-EGFR nanobody 
7D12 did not inhibit c-myc or AEG-1 oncogenes sig-
nificantly (Fig. 10B), suggesting that MaAbNA could 
limit cancer cell proliferation, migration and invasion 
through blocking of the Ha-ras-Akt signal pathway 
downstream of EGFR1 and HER2 [58]. Treatment 
with MaAbNA or the nanobody induced similar in-
hibition of Akt (S473) phosphorylation in 
MDA-MB-231 cells (EGFR1-negative, HER2-positive) 
(Fig. 10C), which further confirmed the synergistic 
effect of EGFR1 and HER2. 
In vivo dynamic distribution and 
tumor-targeting ability of MaAbNA 
The in vivo dynamics of MPA-MaAbNA biodis-
tribution is shown in Figures 11 and 12. 
MPA-MaAbNA was quickly distributed throughout 
the body within approximately 30 minutes after in-
jection, was excreted by the kidneys by 4-hour 
post-injection, and was largely cleared from the body 
within 24 hours. In order to compare the tu-
mor-targeting ability of MPA-MaAbNA to that of the 
MPA-anti-EGFR1 nanobody 7D12 and the 
MPA-ZHER2:4 affibody, nude mice bearing tumor 
xenografts of A549, MDA-MB-231, or MCF-7 cells 
were used. Fluorescence images obtained at different 
time points after administration of MPA-MaAbNA, 
MPA-anti-EGFR1 nanobody 7D12 and MPA-ZHER2:4 
affibody in A549 tumor-bearing mice are shown in 
Fig. 11A. Within 2 hours after injection of the three 
probes, A549 xenografts were identifiable, and the 
intense signal at tumor sites was maintained up to 24 
hours after injection, after which signal intensity 
gradually decreased. By 72 hours post-injection, the 
fluorescent probes had cleared from the body. Tumors 
in mice receiving MPA-MaAbNA displayed higher 
fluorescence intensity than tumors in mice injected 
with the MPA-anti-EGFR1 nanobody 7D12 or 
MPA-ZHER2:4 affibody, with maximal tu-
mor/normal tissue contrast ratios of 5.09, 2.72 and 
2.48, respectively (Fig. 11B). As expected, the admin-
istration of free MaAbNA antibody effectively 
blocked the tumor targeting of all the three probes 
(Fig. 11), confirming its affinity to EGFR1 and HER2 in 
vivo. 
To further explore the specificity of 
MPA-MaAbNA, xenografts of MDA-MB-231 and 
MCF-7 tumor cells were studied. Similar tu-
mor-specific fluorescence signals were detected in 
mice injected with MPA-MaAbNA relative to the 
MPA-anti-EGFR1 nanobody 7D12 treated group (Fig. 
12A), with maximal T/N ratios of 2.48 and 2.53, re-
spectively (Fig. 12D). Free MaAbNA inhibited the 
binding of both MPA-MaAbNA and 
MPA-anti-EGFR1 nanobody 7D12 to tumors (Figs. 
12A, D). In contrast, in MCF-7-derived tumors 
MPA-MaAbNA showed no significant targeting abil-
ity (Figures 12B and 12D), consistent with the 
EGFR1-negative/HER2-negative status of MCF-7 
cells.  
 
Figure 9. Down-regulation of c-jun and c-fos mRNA transcription level in A549, MDA-MB-231 and MCF-7 cells treated with MaAbNA and anti-EGFR1 nanobody 
7D12. Data are given as mean±SD (n=5). *P <0.05. 





Figure 10. A, signal transduction pathways involved in Ha-ras-mediated AEG-1 induction. B, phosphorylation of Akt S473, expression of c-myc and AEG-1 regulated 
by MaAbNA and anti-EGFR1 nanobody 7D12 in A549 (B) and MDA-MB-231 (C) cells. 
 
 
Figure 11. A, Dynamics and tumor-targeting ability of MaAbNA, anti-EGFR1 nanobody 7D12 and ZHER2:4 affibody in A549-bearing nude mice, with or without 
blocking dose of free MaAbNA. B, maximal tumor/normal tissue ratio {T/N ratio= [tumor signal background signal]/ [normal signal (muscle) background signal] × 
100%} calculated from the ROIs at 8-hour post-injection of different probes into A549 tumor-bearing mice with or without blocking dose of free MaAbNA. Data are 
given as mean±SD (n=5). *P <0.05. 





Figure 12. Dynamics and tumor-targeting ability of MaAbNA and anti-EGFR1 nanobody 7D12 in MDA-MB-231-bearing (A), MCF-7-bearing (B) and normal (C) nude 
mice, with or without blocking dose of free MaAbNA. D, maximal tumor/normal tissue ratio calculated from the ROIs at 8-hour post-injection of different probes into 
MDA-MB-231 and MCF-7 tumor-bearing mice with or without blocking dose of free MaAbNA. Data are given as mean±SD (n=5). *P <0.05. 
 
The plots of the maximal T/N ratios for all 
groups of tumor-bearing mice indicated that 
MPA-MaAbNA showed the best targeting to A549 
tumors, and the nude mice bearing A549 tumors 
treated with MPA-MaAbNA had a higher T/N ratio 
than those treated with other univalent-specific 
probes (Figs. 11B and 12D). 
In vivo competitive inhibition of EGF 
tumor-binding 
As shown in Fig. 13, free MaAbNA effectively 
inhibited the in vivo tumor-binding of MPA-EGF, 
which indicated the potential ability of MaAbNA to 
inhibit the EGF-driven tumor progression in vivo. 
Pharmacokinetics of MaAbNA and 
MaAbNA-PEG2000-ADM 
The serum concentrations of MaAbNA and 
MaAbNA-PEG2000-ADM at different post-injection 
time are shown in Supplementary Material: Fig. S3. 
Using WinNonlin software analysis, in accordance 
with the two-compartment model, the pharmacoki-
netic parameters of the two drugs in rats are listed in 
Table 2. 
As indicated in Table 2, the plasma concentra-
tions of both MaAbNA and MaAbNA-PEG2000-ADM 
showed an exponential decline after intravenous ad-
ministration. The elimination of 
MaAbNA-PEG2000-ADM occurred more slowly than 
that of non-modified MaAbNA with a half-life of 
19.46±2.31 h, approximately 2.8 fold longer than 
half-life of MaAbNA (6.9±1.66 h). In contrast to 
MaAbNA, MaAbNA-PEG2000-ADM showed a sig-
nificant decrease in clearance (CL) and a marked in-
crease in the area under the plasma concentra-
tion-time curve (AUC), which suggests that 
MaAbNA-PEG2000-ADM is retained longer in the 
blood circulation than MaAbNA. Taken together, 




these results demonstrate that PEGylation of 
MaAbNA improves its half-life in circulation, and 
promotes its intravascular retention, thus decreasing 
the required administration frequency. 
 
Table 2. Pharmacokinetic properties estimated by two-compartmental model analysis following intravenous bolus injection of MaAbNA 
and MaAbNA-PEG2000-ADM to rats. 
PK properties MaAbNA MaAbNA-PEG2000-ADM 
AUC0-∞ (nmol*h/L) 1044±327 3568±722** 
t1/2α (h) 0.54±0.09 1.43±0.17* 
t1/2β (h) 6.95±2.14 19.46±2.31** 
CL (L/h) 0.061±0.002 0.018±0.01** 
MRT (h) 6.9±1.66 21.2±2.48** 
Vdss (L) 0.45±0.03 0.38±0.03* 
Data are expressed as mean ± SD (n = 6). *P < 0.05, **P < 0.01, MaAbNA vs MaAbNA-PEG2000-ADM. Abbreviations: AUC, area under the curve; CL, clearance; MRT, mean 
residence time; Vdss, steady state volume of distribution. 
 
 
Figure 13. The tumor-binding block of EGF in A549-bearing (A) and MDA-MB-231-bearing (B) nude mice, which was conducted by free MaAbNA. C, maximal 
tumor/normal tissue ratio calculated from the ROIs at 8-hour post-injection of MPA-EGF into different tumor-bearing mice with or without blocking dose of free 
MaAbNA. Data are given as mean±SD (n=5). *P <0.05. 
 
In vivo antitumor efficacy of MaAbNA 
In vivo antitumor efficacy of MaAbNA and 
MaAbNA-PEG2000-ADM were evaluated in 
A549-bearing nude mice by measuring the tumor 
growth of the mice. As shown in Fig. 14A and B, tu-
mors in saline-treated mice grew faster than those of 
the ADM, Cetuximab, Herceptin, 
MaAbNA-PEG2000-ADM or MaAbNA-treated mice. 
Administration of MaAbNA reduced the tumor 
volume by 58% after 15 days of treatment. This de-
crease was higher than that in ADM (~47%) and Ce-
tuximab (~36%)-treated mice, but was lower than that 
observed in Herceptin-treated mice (~70% decrease). 




Treatment with MaAbNA-PEG2000-ADM reduced 
tumor volume by 78%, the greatest extent of tumor 
reduction in any of the groups. Moreover, the body 
weights of mice in different groups gradually in-
creased within the treatment period, indicating no 
apparent physical toxicity, but a decrease of body 
weight (1.2 g) in the ADM-treated group was ob-
served after 13 days treatment (Fig. 14C). The 15-day 
survival rates of mice in the MaAbNA, 
MaAbNA-PEG2000-ADM and Herceptin-treated 
groups were 100%, and that in Cetuximab and ADM 
groups were 83.3% and 66.7% respectively, whereas 
the survival rate of the saline group was drastically 
decreased to 33.3% (Fig. 14D). Histological analysis of 
tumor tissues was used to further confirm the an-
ti-cancer efficacy of MaAbNA (Fig. 14E). Compared to 
saline-treated control, significant amounts of necrotic 
tissue were observed in tumors of all the other 
groups. Furthermore, the extent of tumor necrosis in 
the MaAbNA-PEG2000-ADM group was higher than 
that in tumors treated with any other drugs, which 
was consistent with our in vitro cytotoxicity results in 
A549 cells over-expressing EGFR1 and HER2. 
 
Figure 14. Therapeutic efficacy of MaAbNA in A549 tumor-bearing nude mice. A, tumor volumes of mice under different treatments (saline, MaAbNA, Cetuximab, 
Herceptin, ADM and MaAbNA-ADM, n= 6/group). B, tumors separated from mice under different treatments. C, body weights of mice in different groups. D, the 
15-day survival rates of mice after administration of different drugs. E, the tissue slices of tumors in different groups. The tissue slices of hearts (F) and kidneys (G) in 
saline, MaAbNA-PEG2000-ADM and ADM-treated groups. Data are given as mean±SD (n=5). *P <0.05. 




Heart is the main organ affected by free ADM, 
and the body accumulation of ADM was reported to 
result in significant cardiotoxicity [59]. In addition, the 
free ADM and MaAbNA were approved to be cleared 
out of the body through kidney. Therefore, to inves-
tigate the side effects of MaAbNA-PEG2000-ADM, 
cardiac and renal histological analyses of the treated 
mice were conducted. Sections of myocardium (Fig. 
14F) demonstrated that, compared with the saline 
control, no distinct pathologic changes were found in 
the hearts of MaAbNA-PEG2000-ADM-treated mice. 
In contrast, the hearts of 2 members in the 
ADM-treated group showed noticeable pathologic 
changes, indicating that the MaAbNA ligand specifi-
cally carried ADM molecules to the tumors 
over-expressing EGFR1 and HER2, thus reduced the 
body-accumulation and toxic side effect of ADMs. 
Besides, no significant nephrotoxicity was observed in 
either MaAbNA-PEG2000-ADM or free ADM-treated 
mice (Fig. 14G). 
Discussion 
Several factors determine whether a molecular 
probe is appropriate for a given biological process or 
disease state, such as its pharmacokinetics, possible 
interactions that may results in increased non-specific 
signal, correlation between intensity of the probe 
signal and the levels of molecular target, and low cy-
totoxicity. Recently, various engineered protein 
probes, particularly antibody fragments, protein 
scaffolds and natural protein ligands with more 
compact size, shorter clearance time, and better tumor 
penetration are finding their way in early stage diag-
nosis, therapeutic response monitoring, and person-
alized treatment [60]. To explore the efficacy of a 
novel tumor-targeting ligand with high affinity and 
specificity for tumor cells, a 29 kDa antibody 
(MaAbNA), composed of one anti EGFR1 nanobody 
7D12 and two ZHER2:4 affibodies, was developed 
and shown to possess high affinity for EGFR1 (~4.1 
nM) and HER2 (~4.7 nM). And similar affinity for 
EGFR1 (~6.9 nM) and HER2 (~7.2 nM) was also pos-
sessed by its derivative MaAbNA-PEG2000-ADM. 
This bispecific biomolecule was approved to bind to 
both EGFR1 and HER2, which are over-expressed in 
variety of tumor cells. The avidity of MaAbNA to 
tumor cells was evaluated using three tumor cell lines 
with defined expression of EGFR1 and HER2 receptor 
tyrosine kinases: A549 (EGFR1-positive, 
HER2-positive), MDA-MB-231 (EGFR1-positive, 
HER2-negative), and MCF7 (EGFR1-negative, 
HER2-negative) (Figs. 4, 5). The in vivo tumor target-
ing ability of MaAbNA was consistent with our in 
vitro data and indicated that MaAbNA specifically 
targeted to A549 and MDA-MB-231 xenografts, with 
maximal T/N contrast ratios of 5.09 and 2.48, respec-
tively, at 8 hours post injection, while MaAbNA dis-
played poor targeting ability for the receptor-negative 
MCF-7 (Figs. 11, 12). Moreover, both the in vitro and in 
vivo binding of anti-EGFR1 nanobody 7D12 and 
ZHER2:4 affibody to receptors was successfully 
blocked by free MaAbNA. These results strongly 
suggest that MaAbNA has high affinity and selectiv-
ity for tumor cells overexpressing EGFR1 and/or 
HER2, which further solidifies the potential of using 
MaAbNA as a molecular probe for tumor targeting. 
In vitro MTT assays indicated that MaAbNA ex-
hibited selective toxicity for A549 and MDA-MB-231 
cells, but was non-cytotoxic toward MCF-7 cells and 
the non-malignant cell line L2 (Fig. 7). In contrast, 
adriamycin (ADM) was toxic to all cell lines investi-
gated. In A549 cells, MaAbNA was more cytotoxic 
than either antibody controls (Cetuximab and Her-
ceptin) or adriamycin. Additionally, after modifica-
tion with ADM, the ability of 
MaAbNA-PEG2000-ADM to inhibit A549 cell growth 
was increased, due to the receptor targeting ability of 
MaAbNA. Moreover, as shown in Fig. 8, both 
MaAbNA and MaAbNA-PEG2000-ADM displayed 
significant lower therapeutic efficacy on either 
EGFR1- or HER2- knockdown A549 cells than those 
on non-transferred cells, further confirming their se-
lective cytotoxicity toward tumor cells 
over-expressing EGFR1 and HER2. Furthermore, 
evaluation of the in vivo antitumor therapeutic efficacy 
(Fig. 14) showed that the antitumor activity of 
MaAbNA was higher than that of ADM and an-
ti-EGFR1 Cetuximab, but was lower than that of 
Herceptin, inconsistent with its higher in vitro efficacy 
than Herceptin. This is mainly because MaAbNA 
molecule lacks Fc portion possessed by Herceptin, 
which could be combined with NK cells (nature killer 
cells), thus leading to an antibody-dependent 
cell-mediated cytotoxicity (ADCC) in vivo [61]. How-
ever, MaAbNA-PEG2000-ADM conjugation has 
overcome this limitation (Fig. 14), suppressed the 
proliferation of A549 xenografts to a greater extent 
than either control antibodies (Cetuximab and Her-
ceptin) or ADM and MaAbNA alone. Moreover, the 
15-day survival rates of mice treated with MaAbNA 
or MaAbNA-PEG2000-ADM were 100%, whereas 
only 33.3% of saline-treated tumor-bearing mice re-
mained alive after 15 days. In contrast to the sa-
line-treated control, MaAbNA and its derivative 
MaAbNA-PEG2000-ADM efficiently inhibited tumor 
growth, thus prolonging survival time. Both in vitro 
and in vivo studies confirmed the therapeutic effi-
ciency of MaAbNA and MaAbNA-PEG2000-ADM in 
EGFR1-positive and HER2-positive tumors. Besides, 
from the sections of myocardium, noticeable cardio-




toxicity occurred in the ADM-treated mice (Fig. 14F), 
which may result in their body weight decreasing 
after 13-day treatment of ADM (Fig. 14C). However, 
this cardiotoxicity was not observed in 
MaAbNA-PEG2000-ADM-treated group, indicating 
that the conjugated MaAbNA specifically delivered 
ADMs to tumor tissues, thus reduced the side effects 
of ADM, further demonstrating its selective targeting 
to EGFR1 and HER2 receptors. The PEG2000 modifi-
cation also had the benefit of prolonging the half-life 
of MaAbNA in circulation, which decreased the ad-
ministration frequency of the PEG2000-ADM- 
modified antibody. 
Binding of EGF to the extracellular domain of 
EGFR1 induces receptor dimerization and subsequent 
activation of its intracellular tyrosine kinase domain, 
which leads to the activation of numerous down-
stream signaling pathways, driving cell proliferation 
and other cellular responses. EGFR1 signaling is 
tightly controlled in normal cells, however the aber-
rant overexpression of EGFR1 in tumor cells caused 
by amplification of the EGFR1 gene, over-production 
of EGF that results in abnormal autocrine or paracrine 
stimulation, or by mutations that increase the recep-
tor's tyrosine kinase activity all promote cell prolifer-
ation, differentiation, angiogenesis and inhibition of 
apoptosis, thus favoring tumor growth and metastasis 
[62]. In this study, MaAbNA competed with EGF to 
bind EGFR1 (Figs. 6 and 13), which blocked the acti-
vation of EGF-EGFR1 downstream signaling pathway 
and inhibited tumor cell growth. The activity of HER2 
in cell signaling is mediated by HER2 heterodimeri-
zation with other HER-family receptors and subse-
quent tyrosine phosphorylation of the intracellular 
domain of HER2 [63]. It is now recognized that HER2 
can recruit a diverse set of intracellular signaling 
molecules by heterodimerizing with EGFR1 [64]. 
Therefore, tumors with both EGFR1 and HER2 
over-expression are more invasive, and can be ac-
companied by c-myc overexpression [65, 66], which is 
closely associated with AEG-1 expression. Our min-
iature MaAbNA antibody blocked EGFR1 binding to 
EGF and also blocked the dimerization of EGFRs me-
diated by HER2, thus preventing activation of both 
the EGFR1 and HER2 signaling pathway 
(Ras/Raf/MEK/ERK and PI3K/Akt) [67]. MaAbNA 
also inhibited expression of c-jun, c-fos, c-myc and 
AEG-1, whose expression positively correlates with 
tumor cell proliferation and metastasis (Figs. 9 and 
10). Our results confirm that MaAbNA has the capac-
ity to inhibit cancer cell proliferation, migration and 
invasion, indicating therapeutic potential for 
MaAbNA in metastatic cancers [68]. On the other 
hand, the poor oncogene-regulating ability of an-
ti-EGFR1 nanobody confirms the inhibition of 
MaAbNA due to the synergistic effect of EGFR1 and 
HER2.  
In this study, we have used both in vitro and in 
vivo approaches to investigate the tumor-targeting 
and anticancer capability of MaAbNA, as well as to 
demonstrate the feasibility of the dual targeting ap-
proach. However, further studies are needed for 
MaAbNA to clinical applicability. Immunogenicity is 
an important index to estimate the clinical feasibility 
of antibodies. Although the anti-EGFR1 nanobody 
was reported to have no immunogenicity in preclini-
cal and clinical tests [30, 69], the risk of immunogen-
icity of MaAbNA still exists due to the Staphylococcus 
origin of the affibody molecules. The ABD method 
(human albumin-binding domain) has been used for 
modification of humanized forms of affibodies [70]. 
After tagging with ABD, affibodies display no im-
munogenicity in human serum, which is beneficial for 
use in in vivo tumor imaging and targeting. A variety 
of other technologies and methods [71] could be 
adapted to reduce the immunogenicity of MaAbNA, 
including humanized reform and PEGylation [72], 
which would be conducive to the sequence and 
structure optimization of MaAbNA for potential clin-
ical applications. Moreover, the side effects of 
MaAbNA and MaAbNA-PEG2000-ADM were not 
comprehensively investigated in this study, although 
they exhibited no apparent physical toxicity in mice 
(Fig. 14C). That is because no conclusive evidence 
indicated that the human-receptor specific antibody 
had the similar affinity to the murine receptors, which 
was also verified in our preliminary experiment, the 
targeting ability of MaAbNA to the murine EAC 
xenografts was not as good as that to the human A549 
xenografts over-expressing EGFR1 and HER2. Con-
sequently, the physical toxicity should be evaluated 
on cynomolgus (Macaca fascicularis) monkeys, which 
are the most relevant species for toxicological studies 
of the anti-EGFRs antibodies [73, 74]. Besides, our 
future work includes X-ray single crystal diffraction 
studies of the protein spatial structure and folding of 
MaAbNA, optimization of the MaAbNA formulation 
for optimal administration, as well as to study the 
pharmacokinetics in different in vivo model systems, 
and to reform the sequence of this antibody to im-
prove its targeting efficiency. 
Conclusion 
MaAbNA exhibited significant tumor-targeting 
capability in EGFR1-positive and/or HER2-positive 
tumors, with minimal toxicity toward 
EGFR1/HER2-negative cells and non-malignant cells, 
and represents a potential antitumor agent in 
EGFR1-positive and/or HER2-positive cancer cells. In 
vitro and in vivo studies indicated that MaAbNA 




showed a good anti-tumor efficacy in EGFR1-positive 
and/or HER2-positive cancer cells, such as A549 and 
MDA-MB-231, with minimal cytotoxicity in 
non-tumor cells (L2). Moreover, conjugation of 
MaAbNA to ADM significantly enhanced its tumor 
lethality, inducing a better selective antineoplastic 
efficacy on EGFR1- and/or HER2- overexpressing 
cancer cells than ADM, Cetuximab and Herceptin. 
Overall, our results demonstrate that the MaAbNA 
bispecific antibody is a promising theranostic bio-
molecule for molecular imaging and targeted treat-
ment of EGFR1/HER2- expressing tumors. 
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